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In the early 20th century, hamsters performed acrobatics in
streetside circuses in China (I). Scientists found these Chinese
hamsters useful as hosts for some infectious diseases, but
the strain could not be successfully bred in captivity. One
of the hamster's Middle Eastern cousins, the Syrian hamster,
was successfully raised in the laboratory and has become a
widely used species for study of a variety of human diseases.
In 1962, Homburger et al. (2), at the Bio-Research Institute
in Cambridge, Massachusetts, described muscular dystro-
phy (a hereditary muscle disease that is transmitted in an
autosomal recessive manner) in a strain of Syrian hamsters
(Bio 1.5). Since then, the Bio 14.6 and its descendant lines
have become the most intensively studied strain. In addition
to skeletal muscle involvement, these myopathic hamsters
have progressive cardiac failure. Heart involvement is the
most prominent feature of the disease, and premature death
occurs in most animals from congestive heart failure. At
autopsy, the animals have anasarca, pulmonary congestion
and dilated hearts. This Syrian cardiomyopathic hamster has
become widely accepted as a model for cardiomyopathy
leading to congestive heart failure.
Syrian hamster cardiomyopathy. The cardiac disease
can be divided into four phases (3). During the first or
prenecrotic phase, the animals appear well and there is no
pathologic evidence of disease. The second phase begins
when the animals are about 30 days of age, and is char-
acterized by the appearance of focal myocardial necrotic
lesions. During this phase the animals still appear well and
there is almost no mortality. However, electrocardiographic
(ECG) abnormalities can be seen (4). At about 90 to 120
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days of age, many of the necrotic lesions have healed, few
new lesions appear and hypertrophy of the heart begins. In
this phase, clinically evident disease is usually absent, but
some animals die suddenly and are found to have intra-
myocardial white streaks following the direction of the mus-
cle fibers. These streaks represent calcification of the de-
generating muscle. The fourth, or terminal, phase is marked
by cardiac dilation and overt congestive heart failure. The
animals develop anasarca and pulmonary edema and death
soon follows. Skeletal muscle lesions occur earlier than the
cardiac lesions, and the animals exhibit progressive skeletal
muscle weakness, but the cardiac disease is the most prom-
inent feature of the clinical presentation.
The initial muscle lesions consist of focal myocytolysis
in which myocyte integrity is lost through slow loss of
myofibrils and is replaced by an amorphous material (3).
Gradually, all that is left is the shell of the sarcolemma, or
cell membrane, which eventually collapses and becomes
indistinguishable from the connective tissue of the heart.
Another type of lesion appearing during the peak of the
second phase consists of larger foci of necrotic cells ac-
companied by marked cellular infiltration. Contraction band
necrosis is often seen with this lesion. Later heart lesions
show calcification and fibrosis.
Role of calcium overload in myocardial necrosis. Al-
though calcification is overtly present only in the later le-
sions, calcium may be active in all three types of lesions.
The lesions closely resemble those seen in other pathologic
states where cellular calcium overload produces necrosis.
For example, reperfusion injury commonly produces con-
traction bands (5) with later myocytolysis (6), and the same
lesions can be seen in catecholamine-induced cardio-
myopathy (7). In humans, such lesions are seen I) after
coronary bypass surgery in regions reperfused by the patent
bypassed coronary artery (8); 2) in fatal sclerodermatous
heart disease in which vascular spasm may lead to ischemia
and reperfusion (9); and 3) in cardiomyopathy associated
with pheochromocytoma (10, II). In both reperfusion injury
and catecholamine cardiomyopathy, calcium overload is
thought to playa major role in producing the characteristic
histologic appearance. Thus, it is not surprising that several
investigators have measured increased levels of calcium up-
take in the myocardium of cardiomyopathic hamsters at a
time when lesions are first appearing (12,13).
Other lines of evidence point to calcium overload as a
major determinant of the pathologic features of this disease.
Prolongation of action potential duration has been demon-
strated in cardiomyopathic hamsters (14) and could be ex-
plained by an enhanced slow inward calcium current through
calcium channels. Factor et al. (15) have presented im-
pressive evidence that microvascular spasm is prominent in
this disease. Such spasm may playa role in the development
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of necrosis, perhaps as a consequence of ischemia with
reperfusion. The vasospasm could be caused by increased
calcium ion fluxes across vascular smooth muscle mem-
branes.
Protective effects of verapamil. Persuasive evidence of
a calcium-mediated mechanism of injury is the prevention
of many of the features of the disease by early administration
of the calcium slow channel blocking agent, verapamil.
Jasmin and Solymoss (16) reported that administration of
verapamil before the appearance of necrotic lesions pre-
vented their appearance. These investigators found that other
calcium channel receptor antagonists had similar but less
profound protective effects, as did feeding the animals a
calcium-deficient diet. Lossnitzer et al. (12) confirmed these
protective effects of verapamil against the development of
necrosis and correlated it with prevention of myocardial
calcium overload as measured by 45Ca uptake. Several in-
vestigators have shown that verapamil prevents the occur-
rence of functional abnormalities in addition to protecting
against the necrotic lesions. Factor (15) and Figulla (17)
and their colleagues showed that verapamil prevents micro-
vascular circulatory abnormalities seen in the cardiomyo-
pathic hamsters, and Rouleau et al. (18) found preserved
myocardial contractility in verapamil-treated myopathic
hamsters. Even hamsters in advanced stages of the disease
apparently benefit from verapamil treatment. Markiewicz
et al. (19) found that short periods of verapamil treatment
are sufficient to ameliorate functional and high energy phos-
phate metabolic abnormalities in animals with early cardiac
failure. Educated with these observations, a number of in-
vestigators have studied various myocardial cellular ele-
ments responsible for electrolyte movement inside or outside
of the myocardial cell. Most observed differences were iden-
tified after pathologic changes were present and were limited
to observations of the heart (20-23).
Recently, the dihydropyridine binding site related to the
voltage-dependent slow channel jar calcium entry has been
identified and studied by radioligand binding techniques
(24). One unifying hypothesis for both the myocardial and
vascular lesions would be an increase in the number of
calcium channels (and thereby increased calcium entry) in-
dexed by dihydropyridine binding sites. In studies reported
in 1986 (25), our group found an increased number of bind-
ing sites for the dihydropyridine [3H]nitrendipine in the heart
and brain of 30 day old Syrian hamsters. We also found an
increase in [3H]desmethoxyverapamil binding. This com-
pound labels a second type of calcium antagonist receptor
allosterically linked to the dihydropyridine receptor (26).
However, other receptors not related to the calcium channel
studied by radioligand binding including muscarinic cho-
linergic receptors, alpha) adrenoceptors, dopamine O2 re-
ceptors, adenosine A) receptors and beta-adrenoceptors
showed no increase. Finkel et al. (27) found similar results
nearly simultaneously. Kobayashi et al. (28) in this issue
of the Journal report an increase in the number of dihydro-
pyridine binding sites in the hearts of myopathic animals
and a normal number of adrenoceptors in the early stages
of the disease. Recently, calcium uptake mediated by
Na + -Ca2 + exchange was found to be enhanced in cardiac
sarcolemmal and brain nerve terminal membrane (synap-
tosome) preparations from myopathic hamsters (29). How-
ever, direct physiologic evidence that cellular calcium over-
load occurs because of the increase in calcium channels or
through Na + -Ca2 + exchange has not been obtained, and
the pathologic consequences of the hypothesized calcium
overload in muscle have not been explicitly defined.
Microvascular spasmjollowed by reperjusion could also
contribute to cardiac myocyte calcium overload. Perfusion
abnormalities of the microcirculation have been observed
in the cardiomyopathic hamster (15,17) and their vascular
smooth muscle exhibits increased contractility in response
to pharmacologic stimulation (30). These phenomena could
be caused by increased calcium uptake through the calcium
channel of vascular smooth muscle. The salutary effects of
verapamil could be explained by the potent antispasm action
on vascular smooth muscle as well as an effect on myo-
cardial cells. At this point, it is not possible to distinguish
between a direct effect on the myocardial cell and a sec-
ondary effect mediated by vascular smooth muscle spasm.
Because smooth muscle from the esophagus of these animals
has increased dihydropyridine binding (25), it is possible
that smooth muscle from small vessels might share the same
abnormality.
Other studies of the pathogenesis of Syrian hamster car-
diomyopathy have emphasized biochemical alterations, in-
cluding abnormalities in high energy phosphate metabolism
(31-34) and contractile protein abnormalities (35,36). How-
ever, these findings have largely been in older animals with
more advanced stages of the disease. These abnormalities
could thus be secondary phenomena of failing cardiac mus-
cle rather than underlying mechanisms of the disease.
The study by Kobayashi et al. (28) This study not only
confirms the observation that calcium antagonist receptors
are increased in cardiac tissue in the early stage of the disease
but also substantiates that early administration of verapamil
ameliorates the myopathy. Although some investigators
(37,37a) have not found this increase in dihydropyridine
binding sites, we are now aware of a third confirmatory
study (38).
Kobayashi et al. also suggest a role of free radical pro-
duction in the pathogenesis of the disease. Recently, linkage
between calcium overload and free radical injury related to
myocardial reperfusion has been substantially strengthened.
Reperfusion after ischemia results in a burst of oxygen rad-
icals (39). Free radicals will inactivate the calcium adeno-
sinetriphosphatase responsible for calcium removal from the
myocardial cell (40) and may possibly lead to enzyme changes
that increase calcium entry (41,42). Pathologic findings after
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myocardial ischemia induced by coronary occlusion and
reperfusion are similar to those found in the early stages of
the hamster cardiomyopathy, namely, myocytolysis and
contraction band necrosis. Thus, at least part of the my-
opathy of the Syrian hamster might be explained by a pro-
cess proposed by Sonnenblick et al. (43): coronary spasm
produces recurrent ischemia and reperfusion of myocardial
cells prone to calcium overload, This would explain the
histologic picture of calcium overload and reperfusion-Iike
injury in the early stages of the disease, but it is not clear
that this would explain the later hypertrophic phase and
dilated myopathy. Ongoing ischemia produced by coronary
spasm with secondary necrosis and reactive hypertrophy is
a possible cause, An enhanced inotropic state caused by
increased cell calcium with increased wall stress may also
provide the stimulus for hypertrophy and later cardiac fail-
ure,
Clinical implication. A human paradigm may exist in
that human hypertrophic cardiomyopathy is a disease in
which abnormalities of myocyte calcium handling appear
to playa role, In many patients with hypertrophic cardio-
myopathy, abnormal diastolic function improves after
administration of verapamil. The possibility that these pa-
tients might have an increase in trans-sarcolemmal calcium
flux similar to that in the hamsters is worth further inves-
tigation,
Thus, the Syrian hamster cardiomyopathy appears to pro-
vide one vehicle for understanding human cardiac diseases.
There is a need to further understand the interplay of the
calcium channel, calcium overload and free radical gener-
ation in creating the myopathy of these hamsters. New mo-
lecular biology approaches applied to the Syrian hamster
should be able to identify a specific gene defect in channel
regulation if the increased number of dihydropyridine bind-
ing sites in cardiac and smooth muscle is the primary mech-
anism. The possible relevance of abnormal cellular calcium
handling to heritable hypertrophic myopathy has already
been mentioned, but this model may also provide insights
into human disorders of ischemia and reperfusion, including
scleroderma, in which spasm of small arteries is suspected.
These hamsters may provide more than entertainment in the
Chinese circus.
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